Want to see SE:HNSA full AI Analyst Report?

Hansa Biopharma AB (HNSA) Price & Analysis

17 Followers

HNSA Stock Chart & Stats

kr39.42

-kr1.84(-4.67%)

At close: Jul 27 4:00 PM EDT

kr39.42

-kr1.84(-4.67%)

Day’s Range― - ―

52-Week Rangekr23.52 - kr43.80

Previous CloseN/A

Volume1.15M

Average Volume (3M)792.96K

Market Cap

kr3.50B

Enterprise Valuekr4.01K

Total Cash (Recent Filing)kr552.81M

Total Debt (Recent Filing)kr1.03B

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Nov 05, 2026

EPS Estimate

5.76

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.86

Shares Outstanding101,763,220

10 Day Avg. Volume714,369

30 Day Avg. Volume792,961

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)-31.35

Price to Sales (P/S)12.55

P/FCF Ratio-5.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr103.00

Price Target Upside161.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr442.61M

Bulls Say, Bears Say

Bulls Say

Strong Phase III/confirmatory Clinical DataLarge, statistically significant ConfideS and supportive PAES results materially strengthen the clinical value proposition of imlifidase. Durable efficacy and reduced dialysis dependency improve the case for payer support, label expansion and clinician adoption, underpinning sustainable commercial roll‑out if regulatory approvals follow.

EUR 150M Out‑licensing Deal Strengthens LiquidityThe SERB agreement and EUR 110m upfront meaningfully extend runway and reduce near‑term refinancing pressure. This durable liquidity boost funds U.S. launch readiness, regulatory work, and commercialization investments, lowering solvency risk while management executes market entry and milestone delivery.

U.S. Launch Readiness And Sizable Addressable MarketClear PDUFA timing, experienced commercial hires and focused engagement of the highest‑volume transplant centers provide structural readiness to capture the large CPRA>98% patient pool. A concrete launch plan against a sizable addressable market supports durable revenue opportunity if approval and reimbursement align.

Bears Say

Sharp Revenue Decline And Deep LossesA steep, sustained revenue drop and very large net losses indicate the business lacks current scale to cover fixed costs. Even with attractive product gross margins, persistent top‑line erosion and negative profitability undermine cash generation and increase reliance on external financing, constraining strategic options.

Negative Equity And High Total DebtA negative equity base combined with ~1.03B of debt materially elevates refinancing and solvency risk. Leverage limits flexibility for M&A, partnering or pricing concessions, may trigger lender covenants, and reduces resilience to setbacks in commercialization or regulatory timelines absent sustained profitability or further non‑dilutive funding.

Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating cash flow and free cash flow signal ongoing cash consumption to support operations and launches. Even with the SERB upfront, the company remains dependent on financing until product sales scale, creating dilution or refinancing risk and limiting ability to invest opportunistically or absorb launch setbacks.

Hansa Biopharma AB News

Douglas Tsao Reiterates Buy on Hansa, Maintains $103 Price Target Amid Strategic Pivot and Operational Recovery

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Hansa Biopharma AB. The associated price...

10d ago

Hansa Biopharma Bets Big On U.S. Kidney Launch

Hansa Biopharma (($SE:HNSA)) has held its Q2 earnings call. Read on for the main highlights of the call....

10d ago

Hansa Biopharma bolsters finances with €115m Idefirix deal as clinical data strengthen transplant outlook

The latest update is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma reported second-quarter 2026 revenues...

11d ago

Hansa Biopharma sets Q2 2026 results release and investor call

The latest update is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma will publish its interim...

25d ago

Hansa Biopharma to Highlight Kidney Desensitization Technology at Wedbush PacGrow Renal Summit

Hansa Biopharma AB ( ($SE:HNSA) ) has provided an announcement. Hansa Biopharma will spotlight its work in desensitizing...

1M ago

Hansa Biopharma seals €115m Idefirix licensing deal with SERB

Hansa Biopharma AB ( ($SE:HNSA) ) has provided an update. Hansa Biopharma has closed a €115 million exclusive...

1M ago

Hansa Biopharma: Buy Rating Reiterated as Imlifidase Growth Opportunity Widens; Price Target Maintained at SEK103

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Buy rating on Hansa Biopharma AB. The associated price...

1M ago

Hansa Biopharma’s Phase 3 Kidney Transplant Data Earns Prime Spot at ATC 2026

The latest announcement is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma has built its business...

1M ago

Hansa Biopharma initiated with a Buy at Danske Bank

Danske Bank initiated coverage of Hansa Biopharma (HNSBF) with a Buy rating and SEK 53 price target The...

2M ago

Hansa Biopharma Names Veteran Biotech Executive Adam Cutler as New CFO

An announcement from Hansa Biopharma AB ( ($SE:HNSA) ) is now available. Hansa Biopharma has appointed Adam Cutler...

2M ago

Hansa Biopharma Sets New York Capital Markets Day to Highlight Idefirix and U.S. Launch Plans

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an announcement. Hansa Biopharma will host a Capital Markets Day...

2M ago

Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 103 from...

6M ago

Hansa Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Hansa Biopharma (HNSBF) with an Outperform rating and SEK 69 price target The firm...

7M ago

Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 111 from SEK 132 and...

8M ago

HNSA FAQ

What was Hansa Biopharma AB’s price range in the past 12 months?

Hansa Biopharma AB lowest stock price was kr23.52 and its highest was kr43.80 in the past 12 months.

What is Hansa Biopharma AB’s market cap?

Hansa Biopharma AB’s market cap is kr3.50B.

When is Hansa Biopharma AB’s upcoming earnings report date?

Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 95 days.

How were Hansa Biopharma AB’s earnings last quarter?

Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -kr2.56 earnings per share for the quarter, missing the consensus estimate of -kr0.337 by -kr2.223.

Is Hansa Biopharma AB overvalued?

According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma AB pay dividends?

Hansa Biopharma AB does not currently pay dividends.

What is Hansa Biopharma AB’s EPS estimate?

Hansa Biopharma AB’s EPS estimate is 5.76.

How many shares outstanding does Hansa Biopharma AB have?

Hansa Biopharma AB has 101,763,220 shares outstanding.

What happened to Hansa Biopharma AB’s price movement after its last earnings report?

Hansa Biopharma AB reported an EPS of -kr2.56 in its last earnings report, missing expectations of -kr0.337. Following the earnings report the stock price went down -3.895%.

Which hedge fund is a major shareholder of Hansa Biopharma AB?

Currently, no hedge funds are holding shares in SE:HNSA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hansa Biopharma AB

Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.

Hansa Biopharma AB (HNSA) Earnings & Revenues

Historic Earnings Reports

HNSA Stock 12 Month Forecast

Average Price Target

kr103.00

▲(161.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"kr26","65":"kr65","104":"kr104","45.5":"kr45.5","84.5":"kr84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr103.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,45.5,65,84.5,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,39.676923076923075,44.95384615384615,50.230769230769226,55.50769230769231,60.78461538461538,66.06153846153846,71.33846153846153,76.61538461538461,81.8923076923077,87.16923076923077,92.44615384615383,97.72307692307692,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,39.676923076923075,44.95384615384615,50.230769230769226,55.50769230769231,60.78461538461538,66.06153846153846,71.33846153846153,76.61538461538461,81.8923076923077,87.16923076923077,92.44615384615383,97.72307692307692,{"y":103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,39.676923076923075,44.95384615384615,50.230769230769226,55.50769230769231,60.78461538461538,66.06153846153846,71.33846153846153,76.61538461538461,81.8923076923077,87.16923076923077,92.44615384615383,97.72307692307692,{"y":103,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >